Vamsidhar Velcheti

Vamsidhar Velcheti

Auto-generated profile, based on publicly available information

Vamsidhar Velcheti

Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Chest
Verified
Journal Article
Closed access
MKMonica Khunger
Monica Khunger
SRSagar Rakshit
Sagar Rakshit
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
PMPeter Mazzone
Peter Mazzone
VVVamsidhar Velcheti
Vamsidhar Velcheti

15 June 2017 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
YLYANYAN LOU
YANYAN LOU
JPJames Pellissier
James Pellissier
TBThomas Burke
Thomas Burke
FLFrank Xiaoqing Liu
Frank Xiaoqing Liu
VVVamsidhar Velcheti
Vamsidhar Velcheti
Objectives Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses high levels of programmed death ligand-1 (PD-L1) [tumour proportion score (TPS) ≥50%], from a US third-party public healthcare payer perspective. Methods We conducted a partitioned-survival model with a cycle length of 1 week and a base-case time horizon of 20 years. Parametric models were fitted to Kaplan–Meier estimates of time on treatment, progression-free survival and overall survival from the KEYNOTE-024 randomized clinical trial (patients aged ≥18 years with stage IV NSCLC, TPS ≥50%, without epidermal growth factor receptor (EGFR)-activating mutations or anaplastic lymphoma kinase (ALK) translocations who received no prior systemic chemotherapy) and validated with long-term registry data. Quality-adjusted life-years (QALYs) were calculated based on EuroQoL-5 Dimensions (EQ-5D) utility data collected in the trial. Costs ($US, year 2016 values) for drug acquisition/administration, adverse events and clinical management were included. Costs and outcomes were discounted at 3% per year. A series of deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. Results In the base-case scenario, pembrolizumab resulted in an expected gain of 1.31 life-years (LYs) and 1.05 QALYs and an incremental cost of $US102,439 compared with SoC. The incremental cost per QALY gain was $US97,621/QALY and the incremental cost per LY gain was $US78,344/LY. Conclusions Pembrolizumab is projected to be a cost-effective option compared with SoC platinum-based chemotherapy as first-line treatment in adults with metastatic NSCLC expressing high levels of PD-L1.

1 January 2018 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
PJPrantesh Jain
Prantesh Jain
CJChhavi Jain
Chhavi Jain
VVVamsidhar Velcheti
Vamsidhar Velcheti
Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with impressive clinical activity and durable responses in some patients. This review will summarize the mechanism of action of these drugs, the clinical development of these agents and the current role of these agents in the management of patients with lung cancer. In addition, the review will discuss the role of predictive biomarkers for optimal patient selection for immunotherapy and management of autoimmune side effects of these agents.

1 January 2018 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
AKArjun Khunger
Arjun Khunger
MKMonica Khunger
Monica Khunger
VVVamsidhar Velcheti
Vamsidhar Velcheti
Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase. BRAF-targeted therapies are effective in patients with melanoma and NSCLC harboring BRAF V600E mutation. In both melanoma and NSCLC, dual inhibition of both BRAF and the downstream mitogen-activated protein kinase (MEK) improves response rates compared with BRAF inhibition alone. BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation. Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation.

25 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMonica Khunger
Monica Khunger
PPPradnya Dinkar Patil
Pradnya Dinkar Patil
AKArjun Khunger
Arjun Khunger
MLManshi Li
Manshi Li
BHBo Hu
Bo Hu
VVVamsidhar Velcheti
Vamsidhar Velcheti
The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab. A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model. Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2–40.9) vs 24.2(16.1–36.2) months respectively, p<0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6±21.8 as compared to responders (p = 0.027). Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.

1 May 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MKMonica Khunger
Monica Khunger
PJPrantesh Jain
Prantesh Jain
SRSagar Rakshit
Sagar Rakshit
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
VVVamsidhar Velcheti
Vamsidhar Velcheti